Laura L. Michel

Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials

Carsten Denkert, Fenja Seither, Andreas Schneeweiß et al. · The Lancet Oncology · 2021 · 533 citations

Breast Oncology, Her2-low-positive Breast Cancer, Individual Patient Data +9

CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer

Mario Hlevnjak, Markus Schulze, Shaymaa Elgaafary et al. · JCO Precision Oncology · 2021 · 44 citations · Full text

Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs

Anna S. Berghoff, Yunxiang Liao, Matthia A. Karreman et al. · Molecular Cancer Research · 2020 · 31 citations · Full text

Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer

Andreas Schneeweiß, Laura L. Michel, Volker Möbus et al. · European Journal of Cancer · 2021 · 31 citations

Breast Oncology, Oncology, Pathology +6

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT

Tobias Engler, Peter A. Fasching, Diana Lüftner et al. · Geburtshilfe und Frauenheilkunde · 2022 · 28 citations · Full text